Commentary on ‘‘Microbial Spectrum and Primary Resistance to Rifampicin in Infectious Complications in Vascular Surgery: Limits to the Use of Rifampicin-Bonded Prosthetic Grafts’’

Abstract

Get full access to this article

View all access options for this article.

References

Topel I. , Audebert F. , Betz T. , Steinbauer MG Microbial spectrum and primary resistance to rifampicin in infectious complications in vascular surgery: limits to the use of rifampicin bonded prosthetic grafts . Angiology. In press.

Torsello G. , Sandmann W. , Gehrt A. , Jungblut RM In-situ replacement of infected vascular prostheses with rifampicin soaked vascular grafts: early results. J Vasc Surg. 1993;17(4): 768-773.

Hayes P. , Nasim A. , Sayers RD , et al. In-situ replacement of infected aortic grafts with rifampicin bonded prostheses: the Leicester experience (1992-1998). J Vasc Surg. 1999;30(1): 92-98.

Young RM , Cherry KJ , Davis PM , et al. The results of in-situ prosthetic replacement for infected aortic grafts. Am J Surg. 1999;178(2):136-140.

Bandyk DF , Novotney ML , Back MR , Johnson BL , Schmacht DC Expanded application of in-situ replacement for prosthetic graft infection . J Vasc Surg. 2001;34(3):411-420.

Naylor AR Commentary on: Koshiko S, Sasajima T, Muraki S, Azuma N, Yamazaki K, Chiba K et al. Limitations in the use of rifampicin-gelatin graft against virulent organisms. J Vasc Surg. 2002:35(4):823-824.

Koshiko S. , Sasajima T. , Muraki S. , et al. Limitations in the use of rifampicin-gelatin graft against virulent organisms. J Vasc Surg. 2002;35(4):779-785.